Marex Group plc(MRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MRX Marex Group plc

休市中 11-22 16:00:00 EST

29.18

-0.49

-1.65%

盘后29.18

+0.000.00%

17:34 EST

最高29.75	最低29.01	成交量21.39万
今开29.69	昨收29.67	日振幅2.49%
总市值21.07亿	流通市值8.12亿	总股本7,222万
成交额627.19万	换手率0.77%	流通股本2,782万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"MRX","market":"US","secType":"STK","nameCN":"Marex Group plc","latestPrice":29.18,"timestamp":1732309200000,"preClose":29.67,"halted":0,"volume":213914,"hourTrading":{"tag":"盘后","latestPrice":29.18,"preClose":29.18,"latestTime":"17:34 EST","volume":2180,"amount":63612.4,"timestamp":1732314863263},"delay":0,"floatShares":27824106,"shares":72221800,"eps":2.512811,"marketStatus":"休市中","marketStatusCode":7,"change":-0.49,"latestTime":"11-22 16:00:00 EST","open":29.69,"high":29.75,"low":29.01,"amount":6271909.2797799995,"amplitude":0.024941,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.512811,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":0,"listingDate":1714017600000,"adjPreClose":29.67,"dividendRate":0.018972,"postHourTrading":{"tag":"盘后","latestPrice":29.18,"preClose":29.18,"latestTime":"17:34 EST","volume":2180,"amount":63612.4,"timestamp":1732314863263},"volumeRatio":0.3701335127875649,"impliedVol":0.4222,"impliedVolPercentile":0.7836},"requestUrl":"/m/hq/s/MRX/tweets","defaultTab":"tweets","newsList":[{"id":"2477571627","title":"盟科药业(688373.SH)：MRX-5在澳大利亚Ⅰ期临床试验已完成并达到预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2477571627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477571627?lang=zh_cn&edition=full","pubTime":"2024-10-24 15:46","pubTimestamp":1729755979,"startTime":"0","endTime":"0","summary":"智通财经APP讯，盟科药业 发布公告，公司自主研发的新型苯并硼唑类抗菌药MRX-5在澳大利亚的Ⅰ期临床试验已于近日完成并达到预期目标。MRX-5属于新型抗耐药NTM感染新药，对常见的NTM致病菌具有良好的抗菌活性，且在动物试验和此次人体实验中显示出良好的安全性和药代动力学特性。本次临床研究结果表明，MRX-5在健康成人群体中显现出良好的安全性和耐受性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1576","03347","BK0239","BK1141","BK4127","MRX","688373"],"gpt_icon":0},{"id":"2477337329","title":"Marex Group Plc盘中异动 急速跳水8.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477337329","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477337329?lang=zh_cn&edition=full","pubTime":"2024-10-22 21:31","pubTimestamp":1729603872,"startTime":"0","endTime":"0","summary":"北京时间2024年10月22日21时31分，Marex Group Plc股票出现波动，股价大幅下挫8.82%。Marex Group Plc股票所在的资本市场行业中，整体跌幅为0.49%。其相关个股中，Marketwise, Inc.、阿提夫控股、狮子集团控股涨幅较大，狮子集团控股、Marketwise, Inc.、老虎证券较为活跃，换手率分别为64.03%、5.85%、1.58%，振幅较大的相关个股有Marex Group Plc、Hive Digital Technologies Ltd、狮子集团控股，振幅分别为4.43%、3.92%、3.82%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410222131129f56b912&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410222131129f56b912&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRX","BK4127"],"gpt_icon":0},{"id":"2462462151","title":"分析-法国兴业银行（SocGen）退出，LME公开喊价交易仍在继续，投资者并不急于离场","url":"https://stock-news.laohu8.com/highlight/detail?id=2462462151","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462462151?lang=zh_cn&edition=full","pubTime":"2024-08-28 22:55","pubTimestamp":1724856926,"startTime":"0","endTime":"0","summary":"但 LME 最终妥协了，现在以混合方式运营，使用公开叫价交易来确定实物用户作为交易基准的官方价格，并使用电子系统来确定收盘价。小玩家据一位 LME 高管估计，SocGen 只占公开叫价交易的 6%。一家 LME 环比交易商的高管表示，他们预计其环比业务将被重新分配给一家或多家其余的经纪商。一些 LME 成员认为，电子交易在 COVID-19 期间发挥了作用，全面转向是不可避免的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001093.SGD","LU0067412154.USD","LU0540923850.HKD","LU0831093199.SGD","LU1642822792.SGD","LU0516422366.SGD","LU1226287529.USD","LU1981816686.USD","SNEX","LU0791590937.USD","SG9999001846.SGD","LU0327786744.USD","LU1044874839.SGD","LU0577902454.USD","LU0572944931.SGD","LU0594300419.USD","LU2257852520.SGD","LU0048597586.USD","LU0251144936.SGD","LU0048580855.USD","HKXCY","LU0072913022.USD","LU1993786604.SGD","LU0211977185.USD","LU0140636845.USD","LU1044875133.USD","LU0516423091.SGD","LU0456846285.SGD","LU1366334578.USD","SG9999002463.SGD","LU0634319403.HKD","LU0501845795.SGD","LU0873338254.USD","LU0516422952.EUR","MRX","LU1366334651.USD","80388","BK1610","LU0417516738.SGD","BK1589","BK1131","LU1044876610.USD","LU0791591158.USD","BK1521","BK4127","LU0630378429.USD","HGmain","SG9999004220.SGD","LU0370786039.SGD"],"gpt_icon":1},{"id":"2441219151","title":"盟科药业自主研发的新型注射用多黏菌素类抗菌药MRX-8在中国的I期临床试验顺利完成，并达到预期目标。MRX-8主要用于治疗多重耐药性革兰阴性菌感染。","url":"https://stock-news.laohu8.com/highlight/detail?id=2441219151","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441219151?lang=zh_cn&edition=full","pubTime":"2024-06-05 13:09","pubTimestamp":1717564160,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK1576","BK1583","BK1141","688373","MRX","03347","BK4127","BK0239"],"gpt_icon":0},{"id":"2440405750","title":"盟科药业(688373.SH)：MRX-8中国I期临床试验已完成并达到预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2440405750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440405750?lang=zh_cn&edition=full","pubTime":"2024-06-04 16:07","pubTimestamp":1717488436,"startTime":"0","endTime":"0","summary":"智通财经APP讯，盟科药业 发布公告，公司自主研发的新型注射用多黏菌素类抗菌药MRX-8的中国I期临床试验已于近日完成并达到预期目标。MRX-8是一种用于注射的多黏菌素类抗菌药，主要用于治疗多重耐药的革兰阴性菌感染。传统的多黏菌素类药物由于可导致多发的肾毒性和神经毒性，临床使用受限。本次临床研究结果表明，MRX-8在人体内的药物暴露量随剂量增加成比例增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1141","BK1583","MRX","688373","BK0239","03347","BK4127"],"gpt_icon":0},{"id":"2440140520","title":"【盟科药业(688373.SH)：MRX-8中国I期临床试验已完成并达到预期目标】智通财经APP讯，盟科药业(688373.","url":"https://stock-news.laohu8.com/highlight/detail?id=2440140520","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440140520?lang=zh_cn&edition=full","pubTime":"2024-06-04 16:07","pubTimestamp":1717488436,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","03347","BK1141","688373","MRX","BK4127","BK0239","BK1576"],"gpt_icon":0},{"id":"2440405553","title":"盟科药业：自主研发的新型注射用多黏菌素类抗菌药MRX-8的中国I期临床试验已于近日完成并达到预期目标。","url":"https://stock-news.laohu8.com/highlight/detail?id=2440405553","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440405553?lang=zh_cn&edition=full","pubTime":"2024-06-04 16:03","pubTimestamp":1717488197,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK1141","BK4127","688373","BK1583","BK1576","MRX","BK0239","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.marex.com","stockEarnings":[{"period":"1week","weight":0.0296},{"period":"1month","weight":0.1814},{"period":"3month","weight":0.2038},{"period":"6month","weight":0.4234},{"period":"1year","weight":0.5358},{"period":"ytd","weight":0.5358}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Marex Group plc于2005年11月根据英格兰和威尔士法律成立。Marex是一家多元化的全球金融服务平台，为能源、大宗商品和金融市场的客户提供必要的流动性、市场准入和基础设施服务。他们通过将客户连接到全球交易所并提供一系列执行服务，为客户提供关键服务。","exchange":"NASDAQ","name":"Marex Group plc","nameEN":"Marex Group plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Marex Group plc(MRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Marex Group plc(MRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Marex Group plc,MRX,Marex Group plc股票,Marex Group plc股票老虎,Marex Group plc股票老虎国际,Marex Group plc行情,Marex Group plc股票行情,Marex Group plc股价,Marex Group plc股市,Marex Group plc股票价格,Marex Group plc股票交易,Marex Group plc股票购买,Marex Group plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Marex Group plc(MRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Marex Group plc(MRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}